These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9552949)

  • 1. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators.
    Miettinen TA; Gylling H; Strandberg T; Sarna S
    BMJ; 1998 Apr; 316(7138):1127-30. PubMed ID: 9552949
    [No Abstract]   [Full Text] [Related]  

  • 2. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol.
    Miettinen TA; Strandberg TE; Gylling H
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1340-6. PubMed ID: 10807752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup.
    Miettinen TA; Gylling H
    Atherosclerosis; 2003 Jun; 168(2):343-9. PubMed ID: 12801618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S).
    Lancet; 1995 May; 345(8960):1274-5. PubMed ID: 7746058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment.
    Miettinen TA; Gylling H;
    Clin Chim Acta; 2007 Apr; 379(1-2):53-8. PubMed ID: 17258182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low high-density lipoprotein cholesterol and response to simvastatin therapy in Scandinavian Simvastatin Survival Study (4S).
    Robins S
    Circulation; 2002 Jul; 106(2):e8; author reply e8. PubMed ID: 12105176
    [No Abstract]   [Full Text] [Related]  

  • 7. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
    Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
    Averna M; Zaninelli A; Le Grazie C; Gensini GF
    J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
    Rosen JB; Ballantyne CM; Hsueh WA; Lin J; Shah AK; Lowe RS; Tershakovec AM
    Lipids Health Dis; 2015 Sep; 14():103. PubMed ID: 26336957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.
    Miettinen TA; Gylling H; Lindbohm N; Miettinen TE; Rajaratnam RA; Relas H;
    J Lab Clin Med; 2003 Feb; 141(2):131-7. PubMed ID: 12577049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S).
    Faergeman O; Kjekshus J; Cook T; Pyörälä K; Wilhelmsen L; Thorgeirsson G; Pedersen TR
    Eur Heart J; 1998 Oct; 19(10):1531-7. PubMed ID: 9820992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men.
    Nissinen MJ; Miettinen TE; Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):308-16. PubMed ID: 19695854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease.
    Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY
    Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol.
    Grover SA; Dorais M; Coupal L
    Epidemiology; 2003 May; 14(3):315-20. PubMed ID: 12859032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease.
    Hu G; Cui Y; Jousilahti P; Sundvall J; Girman CJ; Antikainen R; Laatikainen T; Tuomilehto J
    Eur J Prev Cardiol; 2013 Feb; 20(1):89-97. PubMed ID: 22023802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
    Dotti MT; Lütjohann D; von Bergmann K; Federico A
    Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).
    Strandberg TE; Pyörälä K; Cook TJ; Wilhelmsen L; Faergeman O; Thorgeirsson G; Pedersen TR; Kjekshus J;
    Lancet; 2004 Aug 28-Sep 3; 364(9436):771-7. PubMed ID: 15337403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data.
    Armstrong EP; Zachry WM; Malone DC
    J Manag Care Pharm; 2004; 10(3):251-8. PubMed ID: 15228376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.